Viking Therapeutics enters $125M ATM equity offering; terminates prior $75M facility

Viking Therapeutics, Inc.

Entered $125M ATM agreement with Stifel, Truist, and H.C. Wainwright for common stock sales at market prices.
Agents receive 3.0% commission on gross proceeds from sales under the new ATM facility.
Proceeds to fund continued development of VK2809 and VK0214 programs and general corporate purposes.
Terminated prior $75M ATM agreement (Aug 2019) with Stifel and Oppenheimer; no shares ever sold under that facility.
Registration statement for the $125M offering filed but not yet effective; shares may not be sold until effective.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.